Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity

Molecular and Cellular Neuroscience

Volumn 37, Issue 1, 2008, Pages 135-142

  Thornton, Peter ^a   Pinteaux, Emmanuel ^a   Allan, Stuart M ^a   Rothwell, Nancy J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 1BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; UROKINASE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM DISEASE; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; GLIA CELL; INFLAMMATION; NERVE CELL; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMILORIDE; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL DEATH; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 9; NEUROGLIA; NEURONS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; SODIUM CHANNEL BLOCKERS; URINARY PLASMINOGEN ACTIVATOR;

RATTUS;

EID: 37349072821     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2007.09.002     Document Type: Article

References (40)

1. Adair J.C., Charlie J., Dencoff J.E., Kaye J.A., Quinn J.F., Camicioli R.M., Stetler-Stevenson W.G., and Rosenberg G.A. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35 (2004) e159-e162
2. Adair-Kirk T.L., Atkinson J.J., Broekelmann T.J., Doi M., Tryggvason K., Miner J.H., Mecham R.P., and Senior R.M. A site on laminin alpha 5, AQARSAASKVKVSMKF, induces inflammatory cell production of matrix metalloproteinase-9 and chemotaxis. J. Immunol. 171 (2003) 398-406
3. Benchenane K., Castel H., Boulouard M., Bluthe R., Fernandez-Monreal M., Roussel B.D., Lopez-Atalaya J.P., Butt-Gueulle S., Agin V., Maubert E., Dantzer R., Touzani O., Dauphin F., Vivien D., and Ali C. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J. Cell Sci. 120 (2007) 578-585
4. Campbell S.J., Finlay M., Clements J.M., Wells G., Miller K.M., Perry V.H., and Anthony D.C. Reduction of excitotoxicity and associated leukocyte recruitment by a broad-spectrum matrix metalloproteinase inhibitor. J. Neurochem. 89 (2004) 1378-1386
5. Chen Z.L., and Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91 (1997) 917-925
6. Cinelli P., Madani R., Tsuzuki N., Vallet P., Arras M., Zhao C.N., Osterwalder T., Rulicke T., and Sonderegger P. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell. Neurosci. 18 (2001) 443-457
7. Cunningham L.A., Wetzel M., and Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50 (2005) 329-339
8. Falsig J., Porzgen P., Lund S., Schrattenholz A., and Leist M. The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function. J. Neurochem. 96 (2006) 893-907
9. Festuccia C., Angelucci A., Gravina G., Eleuterio E., Vicentini C., and Bologna M. Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement. Exp. Cell Res. 280 (2002) 1-11
10. Gottschall P.E., and Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 64 (1995) 1513-1520
11. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., and Lipton S.A. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25 (2005) 6401-6408
12. Harris J.E., Green J.A., Elkington P.T., and Friedland J.S. Monocytes infected with Mycobacterium tuberculosis regulate MAP kinase-dependent astrocyte MMP-9 secretion. J. Leukoc. Biol. 81 (2007) 548-556
13. Hosomi N., Lucero J., Heo J.H., Koziol J.A., Copeland B.R., and del Zoppo G.J. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 32 (2001) 1341-1348
14. Hu K., Yang J., Tanaka S., Gonias S.L., Mars W.M., and Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J. Biol. Chem. 281 (2006) 2120-2127
15. Jian L.K., and Rosenberg G.A. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic. Biol. Med. 39 (2005) 71-80
16. Krystosek A., and Seeds N.W. Normal and malignant cells, including neurons, deposit plasminogen activator on the growth substrata. Exp. Cell Res. 166 (1986) 31-46
17. Leake A., Morris C.M., and Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci. Lett. 291 (2000) 201-203
18. Lebeurrier N., Liot G., Lopez-Atalaya J.P., Orset C., Fernandez-Monreal M., Sonderegger P., Ali C., and Vivien D. The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol. Cell. Neurosci. 30 (2005) 552-558
19. Ledesma M.D., Da Silva J.S., Crassaerts K., Delacourte A., De S.B., and Dotti C.G. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1 (2000) 530-535
20. Levin J.I., Chen J., Du M., Hogan M., Kincaid S., Nelson F.C., Venkatesan A.M., Wehr T., Zask A., DiJoseph J., Killar L.M., Skala S., Sung A., Sharr M., Roth C., Jin G., Cowling R., Mohler K.M., Black R.A., March C.J., and Skotnicki J.S. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. Bioorg. Med. Chem. Lett. 11 (2001) 2189-2192
21. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., and Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 16 (1997) 2319-2332
22. Menshikov M., Elizarova E., Plakida K., Timofeeva A., Khaspekov G., Beabealashvilli R., Bobik A., and Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem. J. 367 (2002) 833-839
23. Monea S., Lehti K., Keski-Oja J., and Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 192 (2002) 160-170
24. Moonen G., Grau-Wagemans M.P., and Selak I. Plasminogen activator-plasmin system and neuronal migration. Nature 298 (1982) 753-755
25. Moran P., Li W., Fan B., Vij R., Eigenbrot C., and Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem. 281 (2006) 30439-30446
26. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R.M., Silva A.J., Kaczmarek L., and Huntley G.W. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 26 (2006) 1923-1934
27. Opdenakker G., Nelissen I., and Van D.J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2 (2003) 747-756
28. Presta M., Ennas M.G., Torelli S., Ragnotti G., and Gremo F. Synthesis of urokinase-type plasminogen activator and of type-1 plasminogen activator inhibitor in neuronal cultures of human fetal brain: stimulation by phorbol ester. J. Neurochem. 55 (1990) 1647-1654
29. Rosenberg G.A., Navratil M., Barone F., and Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab. 16 (1996) 360-366
30. Saksela O., and Rifkin D.B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4 (1988) 93-126
31. Sariahmetoglu M., Crawford B.D., Leon H., Sawicka J., Li L., Ballermann B.J., Holmes C., Berthiaume L.G., Holt A., Sawicki G., and Schulz R. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 21 (2007) 2486-2495
32. Steffensen B., Xu X., Martin P.A., and Zardeneta G. Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. Matrix Biol. 21 (2002) 399-414
33. Suryadevara R., Holter S., Borgmann K., Persidsky R., Labenz-Zink C., Persidsky Y., Gendelman H.E., Wu L., and Ghorpade A. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44 (2003) 47-56
34. Thornton P., Pinteaux E., Gibson R.M., Allan S.M., and Rothwell N.J. Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J. Neurochem. 98 (2006) 258-266
35. Wang X., Lee S.R., Arai K., Lee S.R., Tsuji K., Rebeck G.W., and Lo E.H. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9 (2003) 1313-1317
36. Wang S., Lee S.R., Guo S.Z., Kim W.J., Montaner J., Wang X., and Lo E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 37 (2006) 1910-1912
37. Wu C.Y., Hsieh H.L., Jou M.J., and Yang C.M. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 90 (2004) 1477-1488
38. Xue M., Hollenberg M.D., and Yong V.W. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J. Neurosci. 26 (2006) 10281-10291
39. Yu Q., and Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13 (1999) 35-48
40. Zhang K., McQuibban G.A., Silva C., Butler G.S., Johnston J.B., Holden J., Clark-Lewis I., Overall C.M., and Power C. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci. 6 (2003) 1064-1071